Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
University of Oklahoma
Aulos Bioscience, Inc.
BicycleTx Limited
EMD Serono
Massachusetts General Hospital
Ocellaris Pharma, Inc.
Dana-Farber Cancer Institute
G1 Therapeutics, Inc.
VA Office of Research and Development
Queen Mary University of London
Pfizer
SWOG Cancer Research Network
EMD Serono
Pfizer
Pfizer
University of Oklahoma
Pfizer
Jules Bordet Institute
Mayo Clinic
University Hospital, Bordeaux
Baylor College of Medicine